Carotid endarterectomy for treatment of carotid in-stent restenosis: long-term follow-up results and surgery experiences from one single centre

Le-Bao Yu,1,2,3,4 Wei Yan,5 Qian Zhang,1,2,3,4 Ji-Zong Zhao,1,2,3,4 Yan Zhang,1,2,3,4 Rong Wang,1,2,3,4 Jun-Shi Shao,1,2,3,4 Dong Zhang1,2,3,4

ABSTRACT

Objective Few studies have reported the surgical treatment of carotid in-stent restenosis (ISR), more data and longer follow-up are needed. We describe the surgical treatment of ISR by standard carotid endarterectomy (CEA) with stent removal, including long-term follow-up in 10 patients from our centre.

Methods Ten patients from our centre who underwent CEA with stent removal for ISR were retrospectively analysed, including nine symptomatic and one asymptomatic ISR of at least 70% with mean age 67.3. The median time between carotid artery stenting and CEA was 17 months (range, 2–54 months).

Results Standard CEA with stent removal was performed in all 10 patients without much technical difficulty (9 male and 1 female, mean age 67.3). Two cases were performed in hybrid operation room. There were a total of three complications that happened in three patients (30%) respectively. An asymptomatic dissecting aneurysm was formed on the petrous internal carotid artery in one patient who was followed up without intervention. In the second case, dissection occurred in the arterial wall distal to the site of the stent after stent removal revealed by intraoperative angiography, and another stent was implanted. The patient sustained temporary hypoglossal nerve dysfunction postoperatively. The third patient suffered cerebral hyperperfusion with complete recovery when discharged. No neurological complications occurred in other seven patients. After follow-up of 25 months (range, 11–54 months), one patient died of rectal cancer without ischaemic attack and restenosis 4 years postoperation; in one patient occurred recurrent symptomatic restenosis (90%) 1 year later; all other patients remained asymptomatic and without recurrent restenosis (>50%) by follow-up carotid ultrasound or CT angiography.

Conclusion It seems that CEA with stent removal is a reasonable choice, by experienced hand, for symptomatic ISR with higher but acceptable complications. The indication of stent removal for asymptomatic ISR needs further observation.

INTRODUCTION

Studies have demonstrated the effectiveness of carotid artery stenting (CAS) and carotid endarterectomy (CEA) for the treatment of carotid stenosis in the prevention of stroke.1–3 High rate of in-stent restenosis (ISR) after CAS has been reported to vary between 5% and 11%,4,5 with the steady increasing cases in CAS, cases of ISR are also increasing in recent years.6–8 Different treatment options including CEA, repeated CAS, percutaneous transluminal angioplasty (PTA) with drug-coated balloons (DCBs) or drug-eluting stents (DES) are available for treatment of ISR, but the optimal technique is not determined.9,10 Most studies generally consist of case reports or small case series, and generally obtain short-term follow-up.11 To the best of our knowledge, until now a total of 39 patients who underwent CEA with stent removal have been reported, no case has been reported recently since 2013.10,12 So, in this study, our experiences in surgical treatment of 10 patients with ISR who underwent CEA with stent removal with long-term follow-up in our centre were reported.

METHODS

Patients

We retrospectively analysed 10 patients who visited the department of neurosurgery in our hospital between September 2012 and November 2016 because of ISR after CAS. Preoperative examination including digital subtraction angiography (DSA) and CT angiography (CTA) (DSA for eight patients, CTA for two patients) of neck arteries was performed in all patients. The clinical data such as age, gender, arterial hypertension, hyperlipidaemia, diabetes mellitus, heart disease, degree and location of initial stenosis and the status of the contralateral side, preoperative symptom and history of transient ischaemic attack (TIA) or stroke were studied.
Surgical treatment

Standard CEA with total removal of the stent was performed in all 10 patients by the same neurosurgeon Dr Zhang. The use of antplatelet medication was not stopped before surgery. Intraoperative electrophysiological monitoring was performed, shunt tube was not used in all cases. The hypoglossal nerve was protected and the carotid bifurcation was completely exposed in order to place clamps proximally and distally. A 3–10 cm length arteriotomy was performed over the stent. The length of the arteriotomy depended on the length and the location of the implanted stent. In all cases, the stent was removed as one single complex with intimal hyperplasia, endarterectomy was done in the usual way without much difficulty. The artery was stitched up in a routine way without patch angioplasty.

Follow-up

Aspirin therapy (300 mg) was administrated per day in 1 week after surgery then long-term aspirin therapy (100 mg) after being discharged. CTA scan was performed within 1 week after surgery in all cases. Carotid ultrasound or CTA was repeated at 3 and 6 months and then yearly.

RESULTS

Clinical characteristics of patients

In total, 10 patients (9 male and 1 female, mean age 67.3) with ISR were treated by CEA with stent removal. Of these, nine patients had hypertension, three patients had hyperlipidaemia, three patients had diabetes mellitus and four patients suffered heart disease (one coronary heart disease and three arrhythmias). All of these underlying chronic diseases were under control after giving medical administration and operations were safe after overall assessment of these risk factors. The patients were suggested of standard medical administration to control their chronic diseases during the follow-up. Nine patients had a symptomatic restenosis, including an ischaemic stroke in one, repetitive TIAs in eight, and one patient had asymptomatic haemodynamically significant restenosis. The rate of ISR in all cases was >70%, comprising contralateral occlusion in two and contralateral severe stenosis in one. The median time of recurrent symptoms after CAS was 6.5 months (range, 1–51 months). The detailed demographics for these cases are provided in table 1.

Surgical and follow-up results

The median time between CAS and CEA was 17 months (range, 2–54 months). Standard CEA was carried out in all patients, a 3–10 cm length arteriotomy was performed over the stent, the stents of all patients were removed as one single complex. No shunt tube and vascular patch were used in any cases. Carotid was opened with normal blood flow after stent removal in most patients, except for one patient where obstruction has happened in the carotid distal portion. A dissection in the arterial wall distal to the site of the stent was demonstrated by intraoperative angiography. As the operation was done in the hybrid operation room (OR), a stent was implanted immediately after angiography. The patient sustained hypoglossal nerve dysfunction while in complete recovery 7 days after surgery and was discharged in good health. An asymptomatic dissecting aneurysm was formed on the petrous internal carotid artery (ICA) in another patient who was followed up without intervention. The operative course of other patients was uneventful. One patient suffered cerebral hyperperfusion presenting with agitation and cognitive disorder in the first day after surgery while in complete recovery when discharged.

During a mean follow-up of 25 months (range, 11–54 months), one patient developed recurrent restenosis of 40% on CTA imaging 5 months after surgery, 80% 10 months after surgery and 90% 1 year after surgery (figure 1). One patient died 4 years later because of rectal cancer without recurrent ischaemic attack. All other eight patients remained asymptomatic, and none of them developed recurrent restenosis of >50% on carotid ultrasound or CTA imaging (table 2).

Table 1 Baseline and clinical characteristics of patients

| N     | %     |
|-------|-------|
| Included patients | 10  |
| Mean age (years) (range) | 67 (54–77)  |
| Sex (M) | 9  | 90 |
| Smoker | 8  | 80 |
| Hypertension | 9  | 90 |
| Hyperlipidaemia | 3  | 30 |
| Diabetes | 3  | 30 |
| Coronary artery disease | 1  | 10 |
| Arrhythmia | 3  | 30 |
| Transient hemispheric ischaemia | 7  | 70 |
| Dizziness | 2  | 20 |

DISCUSSION

So far, the optimal treatment option for ISR has not yet been determined. Different treatment options for ISR have been reported with good outcome including CEA, repeated CAS, PTA with DCBs or DES. However, no prospective studies could be carried out to directly compare these different techniques because of the low incidence. Most studies generally consist of case reports or small case series, and generally obtain short-term follow-up. More cases of ISR treated by new emerging endovascular techniques (DCBs or DES) have been reported than those of ISR treated by CEA with stent removal since 2005. To the best of our knowledge, until now a total of 39 patients who underwent CEA with stent removal have been reported, no case has been reported recently since 2013. Between September 2012 and
November 2016, ten patients had been admitted to the department of neurosurgery in our hospital because of ISR after CAS. We analysed their clinical data and the longest follow-up (range, 11–54 months) had been done. A total of 39 patients who underwent CEA with stent removal and about 200 patients who underwent endovascular treatment have been reported to date. The mean follow-up time was 48.8 months and 16 months, respectively. The rate of stroke between the two groups was not significantly different. Three patients among these 200 patients who underwent endovascular treatment have been reported with recurrent ISR while zero in CEA group. So, CEA with stent removal seems to have a low rate of recurrent ISR. However, CEA with stent removal operation needs more comprehensive assessment and much better physical condition compared with endovascular treatment. Elderly patients at high risk for complications preferred endovascular treatment as it was a relatively simple operation compared with CEA.

Reports have revealed that the rate of in-stent stenosis among studies ranges from 5% to 11%, with an interval time of 12–20 months. In this series, the median time of recurrent symptoms after CAS was 6.5 months (range, 1–51 months), the median time between CAS and CEA was 17 months (range, 2–54 months). All patients are in old age (mean age 67 years) combined with hypertension, which is the most common cause of carotid stenosis. Of these, nine patients were male while one was female. Male seems more common for recurrent stenosis. Earlier studies showed that most of the cases with ISR are asymptomatic, but whether these patients should perform repeat revascularisation at all remains questionable. However, 9 of 10 patients in our study were symptomatic. All patients were discharged without symptom.

In earlier studies, in about 39 patients of CEA with stent removal included, the majority of patients were followed up with good outcomes. No case of recurrent stenosis has been reported. In our study, one patient developed restenosis of 40%, 80% and 90% on CTA imaging 5 months, 10 months and 1 year after stent removal, respectively (figure 1). The patient was a 65-year-old man with hypertension for 7 years. He underwent a left CAS

Figure 1  A 65-year-old man with a clinical diagnosis of in-stent restenosis on his left side by digital subtraction angiography and CTA (A and B, arrow). CTA on the fifth day after operation shows well (C). However, the patient developed recurrent restenosis of 40% on CTA imaging 5 months after surgery (D), 80% 10 months after surgery (E) and 90% 1 year after surgery (F). CTA, CT angiography.
| Preoperation | Degree and location (restenosis) | Operation | Postoperation |
|--------------|---------------------------------|-----------|--------------|
| Period from CAS to recurrent symptom (month) | | Period from CAS to operation (month) | Complication postoperative | Postoperative CTA period <7 days | Follow-up time (month) | Recurrent restenosis |
| 1 | 51 | 70% R-in-stent | 0% LICA | 54 | Dissecting aneurysm | Well | 45 | None |
| 2 | 1 | 70% L-dis-stent | 50% RICA | 24 | None | Well | 43 | None |
| 3 | 18 | 80% L-in-stent | 50% RICA | 36 | Dissection and hypoglossal nerve palsy | Well | 31 | None |
| 4 | 1 | 90% R-dis-stent | 0% LICA | 2 | None | Well | 24 | None |
| 5 | 5 | 90% L-dis-stent | 100% RICA | 6 | Hyperperfusion | Well | 26 | None |
| 6 | 7 | 70% L-in-stent | 0% RICA | 10 | None | Well | 17 | None |
| 7 | 17 | 90% L-in-stent | 100% RICA | 26 | None | Well | 15 | 90% |
| 8 | 6 | 90% L-in-stent | 0% RICA | 37 | None | Well | 11 | None |
| 9 | 7 | 90% L-in-stent | 90% RICA | 8 | None | Well | 54 | Died |
| 10 | - | 90% R-pro-stent | 0% LICA | 4 | None | Well | 4 | None |

CAS, carotid artery stenting; CTA, CT angiography; L-dis-stent, left restenosis on the border between the distal end of stent and internal carotid artery; LICA, left internal carotid artery; R-dis-stent, right restenosis on the border between the distal end of stent and internal carotid artery; RICA, right internal carotid artery; R-in-stent, right inner stent restenosis; R-pro-stent, right restenosis on the border between the proximal end of stent and internal carotid artery.
4 years ago because of severe stenosis in the left ICA and occlusion in the right ICA, severe limb (both arms and legs) weakness and numbness on his left side disappeared after stent implantation. However, he presented with recurrent left limb weakness and numbness 17 months later. CTA demonstrated recurrent stenosis, then the balloon angioplasty was done without stent implantation. Eleven months later, he received CEA with stent removal because of restenosis. As the contralateral ICA was occlusion, his bilateral cerebral hemisphere was supported by the left ICA due to his open anterior communicating artery. Until now, the patient presented with mild limb weakness and numbness on his left side, endovascular treatment was suggested for him.

Until now, the standardised criteria and method for ISR are not defined. A wide range of ISR incidence was reported to be caused by different imaging tools such as CTA, ultrasonography (US) and DSA. Of these, US is the most commonly used technique to monitor ISR after CAS. However, the results of US are not always precise and usually are affected by some factors such as errors between different technicians. In our series, DSA and CTA were the most commonly used techniques to define ISR. DSA was performed in eight patients and CTA in two patients preoperatively. CTA or US was repeated at 3 and 6 months and then yearly after surgery. Preoperative DSA showed that restenosis was observed inner stent in five patients, on the border between the proximal end of stent and ICA in one patient, and on the border between the distal end of stent and ICA in two patients. CTA could show restenosis on the proximal or distal ICA to stent well while not inner stent. So we strongly suggest using DSA for diagnosis of ISR. Of course, CTA was preferred for follow-up examination. All patients were usually required CTA examination within 7 days postoperatively and unobstructed carotid was demonstrated in all patients.

Few perioperative technical difficulties or postprocedural complications of CEA with stent removal have been reported in earlier studies. Our experience is that the complication of stent removal for symptomatic ISR was
relatively higher but acceptable compared with CEA for CAS. The CEA operation for most cases with ISR is relatively normal without much technical difficulties. However, in some cases, if the stent is long enough or placed in distal position out of the surgeon’s control, it will be difficult to operate, nerve dysfunction and dissection in the arterial distal position may happen. In our series, one patient was implanted with a long stent in the right ICA together with a high carotid bifurcation (figure 2). The blood flowed out well from the distal ICA when the stent was removed, but a dissection in the arterial wall distal to the site of the stent was demonstrated by intraoperative angiography after the carotid was closed. As the operation was done in the hybrid OR, a stent was implanted in the distal position of the right ICA immediately after angiography. The patient sustained hypoglossal nerve dysfunction while in complete recovery 7 days after surgery and discharged in good health. Until now, he is well without any evidence of recurrent stenosis 31 months later after surgery. An asymptomatic dissecting aneurysm was formed on the petrous ICA in another patient who was followed up without intervention. The patient was well without symptom until now. The indication for operation of stent removal was not yet defined. In our opinion, intimal hyperplasia was demonstrated in our cases after the stent specimens were dissected and the intimal hyperplasia was stable compared with atherosclerotic plaque. So the indication should be more rigid than normal CEA, symptomatic ISR with severe stenosis is suggested, while stent removal for asymptomatic ISR needs further observation. On the other hand, we strongly suggest that intraoperative angiography is needed after stent removal especially when the stent is long and the carotid bifurcation is very high. The hybrid OR is a good choice for these patients (figure 3) if it is available. Two patients in our series were performed in the hybrid OR, and we demonstrated it is significant.

CONCLUSION
Our experience suggests that CEA with stent removal is a reasonable choice, by experienced hand, for symptomatic

Figure 3 The patient is a 76-year-old man with a clinical diagnosis of in-stent restenosis on his right side by digital subtraction angiography and CTA (A–C, arrows). The operation was done in the hybrid operation room because of the long stent and the high carotid bifurcation. Intraoperative angiography after stent removal and CTA on the sixth day after surgery show well (D, E). The stent was one single complex (F). CTA, CT angiography.
ISR with relatively higher but acceptable complications. The indication of stent removal for symptomatic ISR should be more rigid than normal CEA and the indication for asymptomatic ISR needs further observation. The hybrid OR is a good choice for the patient with ISR if it is available.

Acknowledgements We thank Dr Da-Peng MO (Chief of Invasive Technology Department, Beijing Tiantan Hospital, Capital Medical University) for general support.

Contributors All of the coauthors meet the criteria for authorship and are responsible for specific parts of this work. LBY, WY, QZ, MMJS: conception or design of the work; the acquisition, analysis or interpretation of data for the work. JZZ, YZ, RW, DZ: revising the paper critically for important intellectual content.

Funding The China National Clinical Research Center for Neurosurgical Diseases (NCRC-ND)(2015BAI12B04); The Program of the National Natural Science Foundation of China (81371292).

Competing interests None declared.

Patient consent Obtained.

Ethics approval The Ethics Committee of Tiantan Hospital.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Mantese VA, Timaran CH, Chiu D, et al. The carotid revascularization Endarterectomy versus Stenting trial (CREST): stenting versus carotid endarterectomy for carotid disease. Stroke 2010;41:S31–S34.
2. de Borst GJ, Naylor AR. In the end, it all comes down to the beginning. Eur J Vasc Endovasc Surg 2015;50:271–2.
3. De Borst GJ. RecruitingRCTs comparing CAS, CEA and best medical treatment for asymptomatic carotid Stenosis. J Cardiovasc Surg 2015;56:837–44.
4. de Borst GJ, Ackerstaff RG, de Vries JP, et al. Carotid angioplasty and stenting for post-endarterectomy stenosis: long-term follow-up. J Vasc Surg 2007;45:118–23.
5. Lal BK, Beach KW, Roubin GS, et al. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. Lancet Neurol 2012;11:755–63.
6. van Haften AC, Bots ML, Moll FL, et al. Therapeutic options for carotid in-stent restenosis: review of the literature. J Vasc Interv Radiol 2010;21:1471–7.
7. Marcucci G, Accrocca F, Giordano A, et al. Results of surgical repair of carotid artery in-stent restenosis. J Cardiovasc Surg 2012;53:707–14.
8. Zeller T, Rastan A, Macharzina R, et al. Drug-coated balloons vs. drug-eluting stent for long femoropopliteal lesions. J Endovasc Ther 2014;21:359–68.
9. Siontis GC, Stefanini GG, Mavridis D, et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 2015;386:655–64.
10. Fourrier VE, de Borst GJ. Technical after carotid artery stenting of in-stent restenosis after carotid artery stenting. J Vasc Surg 2016;64:1486–96.
11. Tekeli L, Pleniazek P, Musialek P, et al. Zotarolimus-eluting stent for the treatment of recurrent, severe carotid artery in-stent stenosis in the TARGET-CAS population. J Endovasc Ther 2012;19:316–24.
12. Shah QA, Georgiadis AL, Suri MF, et al. Cutting balloon angioplasty for carotid in-stent restenosis: case reports and review of the literature. J Neuroimagining 2008;18:428–32.
13. Heck D. Results of cutting balloon angioplasty for carotid artery in-stent restenosis in six patients: description of the technique, long-term outcomes, and review of the literature. J Neurointerv Surg 2009;1:48–50.
14. Reichmann BL, van Laanen JH, de Vries JP, et al. Carotid endarterectomy for treatment of in-stent restenosis after carotid angioplasty and stenting. J Vasc Surg 2011;54:87–92.
15. Donas KP, Eisenack M, Torsello G. Balloon angioplasty for in-stent stenosis after carotid artery stenting is associated with an increase in repeat interventions. J Endovasc Ther 2011;18:720–5.
16. Bonati LH, Ederle J, McCabe DJ, et al. Long-term risk of carotid artery stenting in patients randomly assigned to endovascular treatment or reendarterectomy for treatment of in-stent stenosis. J Vasc Surg 2011;54:1167–9.
17. Hynes BG, Ruggiero NJ, Hirsch JA, et al. Carotid stent fracture and restenosis management. Vasc Med 2011;16:436–42.
18. Montorsi P, Galli S, Ravagnani PM, et al. Drug-eluting balloon for treatment of carotid in-stent restenosis: primary preliminary report. J Endovasc Ther 2012:19:734–42.
19. Jost D, Unmuth SJ, Meissner H, et al. Surgical treatment of carotid in-stent-restenosis: novel strategy and current management. Thorac Cardiovasc Surg 2012;60:517–24.
20. Zheng J, Liu L, Cao Y, et al. Carotid endarterectomy with stent removal in management of in-stent restenosis: a safe, feasible, and effective technique. Eur J Vasc Endovasc Surg 2014;47:8–12.
21. Gandini R, Del Giudice C, Da Ros V, et al. Long-term results of drug-eluting balloon angioplasty for treatment of refractory recurrent carotid in-stent restenosis. J Endovasc Ther 2014;21:671–7.
22. Panikh P, Patel A, Patel A, et al. Novel first-in-man use of first ever sirolimus drug coated balloon in carotid in-stent restenosis. J Am Coll Cardiol 2015;65:A1831.
23. Di Gioia G, Campanale CM, Mega S, et al. Percutaneous treatment of recurrent In-Stent restenosis of carotid artery stenting: a Case Report and State-of-the-Art Review. Am J Case Rep 2015;16:558–62.
24. Moon K, Albuquerque FC, Levitt MR, et al. The myth of restenosis after carotid angioplasty and stenting. J Neurointerv Surg 2016;8:1006–10.
25. Zhou W, Lin PH, Bush RL, et al. Management of in-stent restenosis after carotid artery stenting in high-risk patients. J Vasc Surg 2006;43:305–12.
26. Bonati LH, Ederle J, McCabe DJ, et al. Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the carotid and vertebral artery transluminal Angioplasty Study (CANGAS): long-term follow-up of a randomised trial. Lancet Neurol 2009;8:17.

Yu L-B, et al. Stroke and Vascular Neurology 2017;2:e000089. doi:10.1136svn-2017-000089

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Stroke Vascular Neurology: first published as 10.1136/svn-2017-000089 on 24 August 2017. Downloaded from http://svn.bmj.com/ on January 11, 2024 by guest. Protected by copyright.